Market Performance - The Hong Kong stock market indices continued to decline, with the Hang Seng Index falling by 0.57% to 24,980.20, the Hang Seng China Enterprises Index down by 0.67% to 8,945.88, and the Hang Seng Tech Index dropping by 1.26% to 5,472.25, marking a breach of the 25,000-point threshold again [1]. Sector Performance - Large technology stocks showed weak performance, with Kuaishou down nearly 5%, Alibaba down 1.6%, JD.com down 1.46%, and Baidu down 1%. Tencent, NetEase, Meituan, and Xiaomi also experienced declines [3]. - The pharmaceutical sector faced significant adjustments, particularly in internet healthcare and innovative drug stocks, with Tongyuan Kangyi falling nearly 22%, and other notable declines from Gilead Sciences, Nuo Cheng Jianhua, and Fosun Pharma [3]. - Chinese brokerage stocks were collectively weak, with Hongye Futures and Dongfang Securities showing notable declines [3]. Notable Stock Movements - Fuyao Glass surged nearly 14% following its earnings report, indicating strong performance in the glass manufacturing sector [3]. - New consumption concept stocks saw a rise, particularly Pop Mart, which increased by 8.6%, surpassing the 300 HKD mark for the first time [3].

Summary of InnoCare Pharma Earnings Review Company Overview - **Company**: InnoCare Pharma (Ticker: 9969.HK) - **Industry**: Biotechnology Key Financial Highlights - **2Q Revenue**: Rmb350 million, representing a **38% year-over-year increase** [1] - **Orela Sales**: Rmb325 million, a **29% year-over-year increase** compared to guidance of Rmb340 million [1] - **Net Loss**: Narrowed to **Rmb48 million** from **Rmb119 million** in the previous year [1] - **Gross Margin**: Improved to **88.4%** from **85.9%** in 2Q24 [1] - **Collaboration Income**: Rmb25 million contributed to financial performance [1] - **Cash Balance**: Strong cash position of **Rmb7.7 billion** as of 2Q, only slightly lower than the end of 1Q [1] Growth Drivers - **MZL Indication**: Remains the key growth driver for the company [1] - **New Indications**: Newly approved indication for **1L CLL/SLL** expected to drive sales growth in the coming years following NRDL inclusion [1] - **Sales Guidance**: Management maintains a full-year sales growth guidance of **35%+** for 2025, with a high likelihood of exceeding this target based on solid 2Q performance [1] - **New Products**: Potential revenue from newly approved **tafasitamab** and additional business development income anticipated in 2H25 [1] Strategic Initiatives - **Orela Sales Target**: Management targets **US$1 billion** in peak sales for orela, driven by deeper penetration in MZL and potential new indications [2] - **ITP Indication**: Expected to file sNDA in **1H26**, with a market potential of **Rmb1-1.5 billion** [2] - **SLE Treatment**: Plans to change the treatment landscape for SLE with orela as an oral targeted drug [2] - **Commercial Strategy**: Plans to leverage existing hematology franchise for ITP and consider building a separate team for SLE in two years [2] Clinical Development - **Phase 3 Trials**: Plans to start patient enrollment in **2H25** for global phase 3 clinical trials for orela in PPMS and SPMS [3] - **Partnership Strategy**: Management prefers to wait for more validation from preliminary clinical data before licensing out pre-clinical assets [3] - **Clinical Focus**: Shifted focus to global clinical trials for **1L AML and MDS** instead of 1L CLL/SLL for faster development timelines and ROI [3] Earnings Forecast Revision - **Earnings Forecast**: Revised up for 2025E/2026E/2027E by Rmb23 million/Rmb11 million/Rmb11 million to account for higher collaboration income [4] - **Probability of Success (PoS)**: Increased for ITP indication to **80%** from **70%** due to better visibility for sNDA [4] Price Target and Risks - **12-Month Price Target**: HK$20.59 for H-Share and Rmb39.66 for A-Share, reflecting an increase from previous targets [8][9] - **Key Risks**: Include R&D risks for key clinical assets, lack of long-term commercialization track record, pricing uncertainties, potential entry of generic ibrutinib in 2027, and below-expected progress in global expansion [9] Conclusion InnoCare Pharma shows strong growth potential driven by solid sales performance, strategic product development, and a robust financial position. The company is well-positioned to exceed its sales guidance for 2025, with significant opportunities in new indications and collaborations. However, investors should remain cautious of inherent risks associated with R&D and market competition.

Core Viewpoint - Nocera Biotech (09969) experienced a decline of over 4% following the release of its interim results, with shares trading at HKD 19.01 and a transaction volume of HKD 66.54 million [1] Financial Performance - For the six months ending June 30, 2025, Nocera Biotech reported revenue of RMB 731 million, representing a year-on-year increase of 74.26% [1] - The adjusted loss for the period was RMB 15.504 million, a decrease of 93.62% compared to the previous year [1] - The loss attributable to the company's owners was RMB 30.091 million, down 88.51% year-on-year [1] - The loss per share was RMB 0.02 [1] Revenue Drivers - The increase in revenue was primarily driven by strong sales growth of Oubutini and licensing income from Prolium [1] - Revenue from Oubutini rose from RMB 417 million for the six months ending June 30, 2024, to RMB 637 million for the same period in 2025, marking a 52.8% increase due to expanded coverage and an increase in treated patients [1]

Core Viewpoint - The company, Nuo Cheng Jian Hua, experienced a stock decline of over 4% following the release of its interim financial results, despite reporting significant revenue growth and reduced losses [1]. Financial Performance - For the six months ending June 30, 2025, the company reported revenue of RMB 731 million, representing a year-on-year increase of 74.26% [1]. - The adjusted loss for the period was RMB 15.5 million, a decrease of 93.62% compared to the previous year [1]. - The loss attributable to the parent company was RMB 30.1 million, down 88.51% year-on-year [1]. - The earnings per share were reported at a loss of RMB 0.02 [1]. Revenue Drivers - The increase in revenue was primarily driven by strong sales of Obutuzumab and licensing income from Prolium [1]. - Revenue from Obutuzumab rose from RMB 417 million for the six months ending June 30, 2024, to RMB 637 million for the same period in 2025, marking a growth of 52.8% due to an expanded coverage and an increase in treated patients [1].

Core Viewpoint - The company reported strong performance in 1H25, with revenue of 731 million yuan, a year-on-year increase of 74.26%, despite a net loss of 30.09 million yuan, driven by high growth of its core product, Orelabrutinib, and the confirmation of an upfront payment from Prolium for licensing [1][2]. Financial Performance - Revenue for 1H25 reached 731 million yuan, representing a 74.26% year-on-year growth [1]. - The net loss for the period was 30.09 million yuan, indicating a significant narrowing of losses [2]. - Gross margin improved to 89.5%, up 3.8 percentage points year-on-year, primarily due to the rapid growth of Orelabrutinib and the licensing agreement with Prolium [2]. - Sales expenses increased by 55.3% to 244 million yuan, while R&D expenses rose by 5.7% to 450 million yuan [2]. Product Development and Market Expansion - Orelabrutinib sales exceeded expectations, generating 637 million yuan in revenue for 1H25, a 52.8% increase, benefiting from the continued growth of its exclusive indication for MZL [2]. - The company received approval for Tafasitamab for treating DLBCL in May 2025, marking it as the first CD19 monoclonal antibody approved for R/R DLBCL in China [2]. - Orelabrutinib has expanded its indications, receiving a level I recommendation in the CSCO guidelines for 1L CLL/SLL and is set to participate in this year's medical insurance negotiations [2]. - Ongoing global Phase III clinical trials for Orelabrutinib in treating PPMS and SPMS are being initiated, with NDA submission expected in 1H26 for ITP indication [3]. Profit Forecast and Valuation - The company has revised its 2025 loss forecast from 415 million yuan to 319 million yuan and the 2026 forecast from 225 million yuan to 203 million yuan due to better-than-expected sales of Orelabrutinib [4]. - The target prices for A/H shares have been raised by 36.0% and 77.3% to 35.00 yuan and 22.00 HKD, respectively, indicating an upside potential of 10.0% and 10.8% from current prices [4].

Group 1 - Nocera Health (688428.SH) reported its semi-annual results for 2025, with 53 institutional investors holding a total of 108 million shares, representing 6.11% of the total share capital [1] - The top ten institutional investors collectively hold 4.48% of the shares, with a decrease of 0.60 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, eight funds increased their holdings, accounting for a 0.34% increase, while 19 funds decreased their holdings, representing a 1.32% decrease [2] - A total of 24 new public funds disclosed their holdings this period, while 20 funds did not disclose their holdings compared to the previous quarter [2]

Group 1 - Yiling Pharmaceutical's new drug application for "Children's Lianhua Qingwen Granules" has been accepted by the National Medical Products Administration, indicating the company's efforts to expand its respiratory product line [1] - During the COVID-19 pandemic, Yiling Pharmaceutical experienced significant revenue growth due to Lianhua Qingwen, but performance has normalized as demand decreased [1] Group 2 - East China Pharmaceutical reported a revenue of 21.675 billion yuan for the first half of 2025, a year-on-year increase of 3.39%, and a net profit attributable to shareholders of 1.815 billion yuan, up 7.01% [2] - The company is focusing on innovation in weight loss, oncology, and autoimmune disease sectors, which may lead to a valuation shift from "stable" to "growth" as new products are launched [2] Group 3 - Innovent Biologics reported a revenue of 731 million yuan for the first half of 2025, a 74.26% increase year-on-year, but incurred a net loss of 30.0914 million yuan, an improvement from a loss of 262 million yuan in the same period last year [3] - The strong growth in revenue is attributed to increased sales of its core product, Aobutini, which reached 637 million yuan, a 52.84% year-on-year increase [3] - Future sales growth is expected as the indications for Aobutini expand [3] Group 4 - Zai Lab announced that its investigational product ZGGS34 has received FDA approval for clinical trials aimed at treating advanced solid tumors, marking a significant step in the company's international innovation efforts [4] - Preclinical studies have shown that ZGGS34 exhibits significant tumor suppression effects across various cancer models [4] - However, ZGGS34 is still in the early stages of clinical development, and the path to market remains lengthy, with inherent risks associated with drug development [4]

Group 1 - The company is a high-tech innovative biopharmaceutical enterprise focusing on unmet clinical needs in oncology and autoimmune diseases, with strong R&D capabilities [1][2] - In the first half of 2025, the company achieved a net profit attributable to shareholders of -30 million yuan, a significant improvement of 88.51% compared to -262 million yuan in the same period last year [1] - The company increased its R&D investment to 450 million yuan, up 6.71% year-on-year, reflecting its commitment to new technology platform development and clinical trials [1] Group 2 - The company plans to use its own funds not exceeding 476.336 million yuan to acquire the remaining 7% equity of its subsidiary Guangzhou Nocare Pharmaceutical Technology Co., Ltd., aiming for 100% ownership [31][34] - This acquisition does not constitute a related party transaction or a major asset restructuring as defined by regulations [31][32] - The board of directors approved the acquisition without needing shareholder meeting approval, indicating a streamlined decision-making process [32][33] Group 3 - The company announced a delay in the "Information Technology Construction Project" to September 2027 and plans to inject 107 million yuan into its wholly-owned subsidiary Beijing Tianshi Pharmaceutical Technology Co., Ltd. to support project implementation [46][49] - The delay is attributed to the complexity of the project and the need for adjustments to ensure quality and effectiveness [49][54] - The company will continue to manage the raised funds strictly according to regulatory requirements, ensuring transparency and accountability [53][54] Group 4 - The company has revised and established certain internal governance systems in accordance with A-share listing rules, enhancing its governance framework [60] - The revised governance documents will be disclosed on the Shanghai Stock Exchange website, ensuring compliance and transparency [60] Group 5 - A significant shareholder, King Bridge Investments Limited, reduced its stake from 7.00% to 6.92%, which does not trigger a mandatory tender offer and does not affect the company's control structure [61][62] - The company will continue to monitor and disclose any further changes in shareholder equity as required [62]

Core Viewpoint - The company reported a significant increase in revenue for the first half of 2025, but continued to face net losses and negative cash flow from operating activities. Financial Performance - The company's operating revenue for the first half of 2025 was approximately 731.43 million, compared to 419.74 million in the same period last year, representing a year-on-year increase of 74.2% [2] - Pharmaceutical sales revenue was approximately 641.23 million, up from 417.82 million year-on-year [2] - The total profit for the period was a loss of approximately 30.58 million, an improvement from a loss of 267.92 million in the previous year [2] - The net profit attributable to shareholders was a loss of approximately 30.09 million, compared to a loss of 261.84 million in the same period last year [2] - The net cash flow from operating activities was a loss of approximately 61.82 million, an improvement from a loss of 282.53 million year-on-year [2] Profitability Metrics - The company's weighted average return on equity for the first half of 2025 was -0.45%, an increase of 3.28 percentage points year-on-year [19] - The return on invested capital for the first half of 2025 was -0.82%, an increase of 4.09 percentage points compared to the same period last year [19] Cash Flow Analysis - The net cash flow from financing activities was approximately 28.33 million, an increase of 60.90 million year-on-year [23] - The net cash flow from investment activities was approximately 62.30 million, compared to a loss of 118 million in the previous year [23] Asset and Liability Changes - As of the end of the first half of 2025, the company's cash and cash equivalents increased by 11.86% compared to the end of the previous year, while trading financial assets decreased by 90.11% [33] - Short-term borrowings decreased by 41.73%, while accounts payable increased by 38.71% [36] Shareholder Composition - New shareholders include E Fund Medical Healthcare Industry Mixed Securities Investment Fund and Huatai-PineBridge Innovation Medicine Theme Mixed Securities Investment Fund, replacing previous shareholders [52] - HKSCC NOMINEES LIMITED holds 50.02% of the total share capital, with a slight increase of 1.46 percentage points [53]

Core Viewpoint - Nocera Biopharma (09969.HK) reported a significant revenue increase of 74.26% year-on-year for the first half of 2025, driven by the sales growth of its core product, Obinutuzumab (brand name: Yinuokai), and a licensing agreement with Prolium [1] Financial Performance - The company's revenue for the first half of 2025 reached 731 million yuan, while the net profit attributable to shareholders was a loss of 30.09 million yuan, which represents a narrowing of losses compared to the previous year [1] - Drug revenue increased by 53.5% year-on-year to 640 million yuan, with Obinutuzumab's revenue growing by 52.8% to 637 million yuan [2] Product Development and Approvals - Obinutuzumab has been approved for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in adult patients, marking its first indication as a first-line therapy [2] - The company’s other product, Tanshimab (brand name: Mingnuokai), received approval for use in combination with Lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [2] Commercialization Efforts - Nocera Biopharma increased its sales and distribution expenses by approximately 55% year-on-year to 244 million yuan, primarily due to commercial expansion and share-based payment adjustments [3] - The company has submitted an application for Tanshimab to be included in the commercial insurance innovative drug directory, which has passed preliminary review [3] Strategic Initiatives - The company announced its second business development (BD) transaction in January, partnering with Connoa to license Prolium for the development and commercialization of a bispecific antibody [4] - Nocera Biopharma aims to enhance its global presence and plans to accelerate innovation, commercialization, and internationalization over the next 3-5 years, targeting multiple new drug approvals and international expansions [4] Research and Development - The company’s R&D expenses increased by 6.9% year-on-year to 450 million yuan, reflecting its commitment to advancing clinical projects and building a differentiated research platform [4] - Nocera Biopharma is advancing its BCL2 inhibitor "mesutoclax (ICP-248)" and a new generation TRK inhibitor zurletrectinib (ICP-723), with the latter's new drug application accepted for priority review in China [5][6] Financial Position - As of June 30, 2025, the company held approximately 7.68 billion yuan in cash and cash equivalents, indicating a strong financial position within the biotech sector [6]